December 19, 2016
Novocure’s Optune® (NovoTTF-100A) Approved in Japan for the Treatment of Newly Diagnosed Glioblastoma
Optune is the first MHLW-approved therapy in more than a decade to demonstrate statistically and clinically significant extension of survival in newly diagnosed GBM patients December 19, 2016 07:27 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that the Japanese Ministry… Read More
learn more
December 15, 2016
Novocure to Participate in 35th Annual J.P. Morgan Healthcare Conference
December 15, 2016 07:00 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today that it will participate in the 35th Annual J.P. Morgan Healthcare Conference on Jan. 11, 2017, in San Francisco. William Doyle, Novocure’s Executive Chairman, will speak on behalf of the company and… Read More
learn more
December 12, 2016
Novocure Presents Second Cohort of Phase 2 Pilot PANOVA Trial Results Suggesting Tumor Treating Fields Plus Nab-Paclitaxel and Gemcitabine may be Safe as First-Line Treatment and may Improve One-Year Survival Rate of Patients with Advanced Pancreatic Cancer
Progression free survival and one-year survival rate of patients treated with Tumor Treating Fields plus nab-paclitaxel and gemcitabine were more than double those of nab-paclitaxel and gemcitabine-treated historical controls No serious adverse events related to TTFields were reported December 12, 2016 04:00 PM Eastern… Read More
learn more
December 12, 2016
Novocure Presents Phase 2 Pilot INNOVATE Trial Results Suggesting Tumor Treating Fields Plus Paclitaxel may be Safe as First-Line Treatment and may Improve Survival of Patients with Recurrent Ovarian Cancer
Topline results demonstrate strong efficacy signals and support planning of phase 3 pivotal trial of TTFields in recurrent ovarian cancer December 12, 2016 04:00 PM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) presented data on Dec. 12, 2016, from its phase 2 pilot… Read More
learn more
December 8, 2016
Novocure Announces Agenda for Research and Development Day on Dec. 12, 2016
Speakers will share new data from Novocure’s phase 2 pilot trials in pancreatic and ovarian cancers December 08, 2016 07:42 AM Eastern Standard Time ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure (NASDAQ: NVCR) announced today the agenda for the company’s research and development day for analysts and investors, which will… Read More
learn more
